Vertex Pharmaceuticals Outshines Amgen as Top Biotech Stock

Two leading biotech stocks in the US are Amgen and Vertex Pharmaceuticals. To determine which one is a better buy, let's examine their financials, risk profiles, and valuations.

Amgen operates as a global biotechnology powerhouse, focusing on serious diseases across oncology, inflammation, and rare disease segments. The company serves a broad patient base through its diversified portfolio of products. In FY 2025, revenue reached nearly $36.7 billion, representing a roughly 9.9% increase from the prior year.

Amgen has a debt-to-equity ratio of approximately 6.3x and a current ratio of roughly 1.1x. The company generates significant free cash flow, which provides ample funds for dividends and further research. However, its customer concentration adds a layer of risk to the business, with nearly 77% of worldwide gross revenues coming from wholesalers like McKesson, Cencora, and Cardinal Health.

Vertex Pharmaceuticals, on the other hand, has built a dominant position in the treatment of cystic fibrosis through its highly effective drugs. The company sells its products primarily to specialty pharmacies and major wholesalers, maintaining a high level of control over its specialized market. In FY 2025, revenue reached nearly $12.1 billion, growing close to 9.6% year-over-year.

Vertex has a very conservative financial position with a debt-to-equity ratio of approximately 0.2x and a current ratio of nearly 2.9x. The company's high level of profitability is characteristic of its focused business model. However, it faces risks from pricing pressures and potential changes to healthcare policy.

Considering the two companies' financials, risk profiles, and valuations, Vertex Pharmaceuticals appears to be a more attractive option for long-term investors. Its cystic fibrosis franchise is one of the most dominant in the history of specialty pharma, with its products reaching nearly all patients with the disease.